Laura Soucek (born 1973) is a Group Leader at VHIO (the ), Research Professor at ICREA, and CEO of Peptomyc S.L. She works on the Myc oncoprotein, the deregulation of which occurs during almost all cancers. Soucek has designed a dominant negative variant, Omomyc, which allows her to investigate the benefits of inhibiting Myc in cancer.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Laura Soucek (es)
- Laura Soucek (en)
|
rdfs:comment
| - Laura Soucek (Velletri, 1973) es una investigadora italiana, líder de grupo en el Instituto de Oncología Vall d'Hebron, profesora de investigación en ICREA (siglas en inglés para la ), y CEO de Peptomyc S.L. Trabaja con la oncoproteína Myc, que se desregula cuando el organismo sufre cáncer. Soucek ha diseñado una variante dominante negativa, Omomyc, que le permite investigar los beneficios de inhibir el Myc durante el cáncer. (es)
- Laura Soucek (born 1973) is a Group Leader at VHIO (the ), Research Professor at ICREA, and CEO of Peptomyc S.L. She works on the Myc oncoprotein, the deregulation of which occurs during almost all cancers. Soucek has designed a dominant negative variant, Omomyc, which allows her to investigate the benefits of inhibiting Myc in cancer. (en)
|
foaf:name
| |
name
| |
birth place
| |
birth place
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
workplaces
| - Vall d'Hebron Institute of Oncology, ICREA, UAB (en)
|
dbp:wikiPageUsesTemplate
| |
alma mater
| |
influences
| |
has abstract
| - Laura Soucek (Velletri, 1973) es una investigadora italiana, líder de grupo en el Instituto de Oncología Vall d'Hebron, profesora de investigación en ICREA (siglas en inglés para la ), y CEO de Peptomyc S.L. Trabaja con la oncoproteína Myc, que se desregula cuando el organismo sufre cáncer. Soucek ha diseñado una variante dominante negativa, Omomyc, que le permite investigar los beneficios de inhibir el Myc durante el cáncer. (es)
- Laura Soucek (born 1973) is a Group Leader at VHIO (the ), Research Professor at ICREA, and CEO of Peptomyc S.L. She works on the Myc oncoprotein, the deregulation of which occurs during almost all cancers. Soucek has designed a dominant negative variant, Omomyc, which allows her to investigate the benefits of inhibiting Myc in cancer. (en)
|
institution
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
alma mater
| |
influenced by
| |
foaf:isPrimaryTopicOf
| |
is foaf:primaryTopic
of | |